Wisconsin-based life sciences company Eversana and New York data sciences firm WorldQuant Predictive (WQP) aim to improve patient adherence and outcomes through real-time artificial intelligence and machine learning.

Eversana, a pioneer of commercial services to the global life sciences industry, has partnered with WQP, a specialist in quantitative predictions and data-driven decisions through a cloud-based AI platform, to improve the end result for patients.

The combination of WQP’s AI platform with the Actics by Eversana technology could increase patient adherence and outcomes by improving the precision of predictions, enabling proactive commercialisation services to reach and guide providers and patients.

“AI and machine learning are rapidly moving from the hobby-shop approach to streaming platform scale,” said Brigham Hyde, president of data and analytics at Eversana. “The integration of WorldQuant Predictive’s platform with Eversana’s commercialisation is built for the modern healthcare data ecosystem and democratises model tuning and optimisation in a way that ensures maximum performance for our commercial services.”

WQP lets organisations create and apply predictive technology to large pools of third-party data without handing over proprietary assets, protecting both the data and patients’ privacy. Through the integration of WQP’s platform with Actics and Eversana’s end-to-end commercialisation services, Eversana can rapidly make predictions and take actions on the insights gleaned from linked electronic health records, claims, clinical trials and/or genomic data. This can improve patient outcomes and transform the patient experience.

Actics is being leveraged into the launch and commercialisation strategies for multiple pharmaceutical and digital therapies and works seamlessly with Eversana’s integrated commercial services platform designed to solve global pricing, access, reimbursement, real-world evidence, adherence and product delivery problems in the life sciences sector. Multiple pharmaceutical and digital therapies are leveraging Actics for launch and commercialisation strategies.

“We are very excited to partner with Eversana to improve delivery of vital medications to patients who need them,” said James Golden, CEO of WorldQuant Predictive. “Overlaying WQP’s platform, global research network, auto ML capabilities and enhanced data libraries will allow Eversana’s pharmaceutical clients to more precisely predict and enhance patient adherence. With this collaboration, Eversana can deliver better support for their commercial pharmaceutical customers, patients and providers.”

Through this multi-year partnership, Eversana is WQP’s preferred services partner for life sciences and will extend WQP’s platform and real-world data capabilities with scaled commercialisation, data and outcome science services for life sciences.

This partnership follows Eversana’s recent announcements outlining data and infrastructure partnerships with Symphony Health, Compile and Datavant for Actics data and predictive technology.

Eversana serves more than 500 organisations, including start-ups and established pharmaceutical companies, to advance life sciences.

WQP specialises in quantitative predictions, leveraging artificial intelligence and machine learning to create a predictive edge for organisations. It was founded by Igor Tulchinsky. The firm’s cloud-based platform enables data-driven decisions at scale.